• Sherica Celine
    Sherica Celine
    • 7 months ago
    • Practical Guidance Journal
    • pa

    Artificial Intelligence (AI) Considerations in Acquisition Agreements

    By: Erin Hanson , Arlene Arin Hahn , Sahra Nizipli , and Jordan Hill , WHITE & CASE LLP THIS ARTICLE SUMMARIZES VARIOUS INTELLECTUAL PROPERTY AND TECHNOLOGY (IP/IT) PROVISIONS, including sample definitions and representations and warranties, for...
  • Vinayak Kohli
    Vinayak Kohli
    • over 8 years ago
    • Practical Guidance Journal
    • pa

    A Briefing on Emerging Issues Impacting Transactional Practice - Summer 2016

    SEVENTEEN STATE “NEW ENERGY FUTURE” COALITION FORMED GOVERNOR ANDREW M. CUOMO AND 16 OTHER GOVERNORS signed the Governors’ Accord for a New Energy Future. The accord describes six shared goals, diversification of energy generation...
  • Sherica Celine
    Sherica Celine
    • over 3 years ago
    • Practical Guidance Journal
    • pa

    A Briefing on Emerging Issues Impacting Transactional Practice - Winter 2017

    FEDERAL COURT FAST TRACKS REVIEW OF RULING BLOCKING IMPLEMENTATION OF OVERTIME REGULATIONS THE FIFTH CIRCUIT COURT OF APPEALS ISSUED A BRIEF order December 8 granting expedited review of a November 22 ruling by a federal judge in the Eastern District...
  • Vinayak Kohli
    Vinayak Kohli
    • over 9 years ago
    • Practical Guidance Journal
    • pa

    Understanding At-the-Market Offerings

    By: Michael Rave , Day Pitney LLP LEXIS PRACTICE ADVISOR RESEARCH PATH: Securities & Capital Markets > Post-IPO Equity Offerings > Other Equity Offerings > Practice Notes There are various ways in which companies can attempt to raise...
  • Vinayak Kohli
    Vinayak Kohli
    • over 4 years ago
    • Practical Guidance Journal
    • pa

    Avoiding False Claims Act Risks Relating to Federal Funding for Coronavirus (COVID-19) Relief

    By: Matthew D. Jenkins , Hunton Andrews Kurth LLP This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response...
<>